Bodycote /£BOY
1D1W1MYTD1Y5YMAX
Capital at risk
About Bodycote
Bodycote plc (BOY) specializes in heat treatment and thermal processing services aimed at improving the properties of metals and alloys. The company operates within the industrial sector, providing vital services to enhance material performance across multiple industries including aerospace, automotive, and energy. Founded in 1923, Bodycote today provides thermal processing services globally, contributing to the manufacturing processes of various high-performance components.
- Ticker
- £BOY
- Sector
- Industrials
- Primary listing
- LSE
- Employees
- 3,921
- Headquarters
- Macclesfield, United Kingdom
- Website
- www.bodycote.com
Bodycote Metrics
BasicAdvanced
£1.6B
28.02
£0.34
1.35
£0.23
2.45%
Price and volume
Market cap
£1.6B
Beta
1.35
52-week high
£9.58
52-week low
£5.85
Average daily volume
1.3M
Dividend rate
£0.23
Financial strength
Current ratio
1.14
Quick ratio
0.963
Long term debt to equity
32.469
Total debt to equity
34.932
Dividend payout ratio (TTM)
68.04%
Interest coverage (TTM)
17.93%
Profitability
EBITDA (TTM)
174.5
Gross margin (TTM)
14.04%
Net profit margin (TTM)
7.87%
Operating margin (TTM)
14.80%
Effective tax rate (TTM)
25.92%
Revenue per employee (TTM)
£190,000
Management effectiveness
Return on assets (TTM)
6.45%
Return on equity (TTM)
9.35%
Valuation
Price to earnings (TTM)
28.016
Price to revenue (TTM)
2.201
Price to book
2.62
Price to tangible book (TTM)
5.14
Price to free cash flow (TTM)
25.348
Free cash flow yield (TTM)
3.95%
Free cash flow per share (TTM)
0.371
Dividend yield (TTM)
2.45%
Growth
Revenue change (TTM)
1.68%
Earnings per share change (TTM)
114.51%
3-year revenue growth (CAGR)
-2.81%
10-year revenue growth (CAGR)
2.85%
3-year earnings per share growth (CAGR)
-8.41%
10-year earnings per share growth (CAGR)
-0.82%
3-year dividend per share growth (CAGR)
2.56%
10-year dividend per share growth (CAGR)
4.30%
What the Analysts think about Bodycote
Analyst ratings (Buy, Hold, Sell) for Bodycote stock.
Analyst projections of the future price of Bodycote stock.
Bulls say / Bears say
H1 2026 core organic revenue grew 9.6%, adjusted operating profit rose 10.7% and adjusted EPS increased 18.3%; management maintained its full-year outlook for organic growth and margin improvement. (LSE RNS)
Exposure to faster-growing specialist markets is improving: Aerospace & Defence revenue increased 25%, Industrial Gas Turbines 11%, and Specialist Technologies delivered 16.7% organic revenue growth in H1. (LSE RNS)
Bodycote is investing to expand capacity in aerospace, defence, HIP and additive manufacturing, including upgrades across its eastern U.S. network and further European capacity, supporting potential medium-term growth. (Bodycote)
Automotive remains a drag, particularly in Europe, while management says some regional Automotive and Industrial markets are sufficiently challenged that it is considering expanding the Optimise restructuring programme. (LSE RNS)
Cash generation weakened despite higher profit: H1 free cash flow fell to £14.5m from £18.0m, while net debt excluding leases rose to £135.2m from £104.8m at December 2025 after dividends, buybacks, acquisition spending and restructuring costs. (LSE RNS)
The growth programme carries near-term execution risk: Bodycote expects higher second-half investment, set-up costs and variable pay, while FY2025 revenue declined 4.0% and adjusted operating profit fell 11.4% year over year. (Bodycote FY2025 Results)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Bodycote Financial Performance
Revenues and expenses
Bodycote Earnings Performance
Company profitability
Upcoming events
Funds containing Bodycote
AllGBPEURUSD
Fund name | Fund size | £BOY weighting |
|---|---|---|
iShares FTSE 250£MIDD | £661M | 0.51% |
Vanguard FTSE 250£VMID | £1.6B | 0.39% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.13% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.13% |
L&G Global Quality Dividends£LDGG | £279M | 0.04% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.